A greenhouse pot experiment was conducted to study the impact of arbuscular mycorrhizal fungi−Glomus versiforme (Gv) and Rhizophagus intraradices (Ri) on the growth, Cd uptake, antioxidant indices [glutathione reductase (GR), ascorbate peroxidase (APX), superoxide dismutase (SOD), catalase (CAT), ascorbate (ASA), glutathione (GSH) and malonaldehyde (MDA)] and phytochelatins (PCs) production of Lonicera japonica in Cd-amended soils. Gv and Ri significantly increased P acquisition, biomass of shoots and roots at all Cd treatments. Gv significantly decreased Cd concentrations in shoots and roots, and Ri also obviously reduced Cd concentrations in shoots but increased Cd concentrations in roots. Meanwhile, activities of CAT, APX and GR, and contents of ASA and PCs were remarkably higher in Gv/Ri-inoculated plants than those of uninoculated plants, but lower MDA and GSH contents in Gv/Ri-inoculated plants were found. In conclusion, Gv and Ri symbiosis alleviated Cd toxicity of L. japonica through the decline of shoot Cd concentrations and the improvement of P nutrition, PCs content and activities of GR, CAT, APX in inoculated plants, and then improved plant growth. The decrease of shoot Cd concentrations in L. japonica inoculated with Gv/Ri would provide a clue for safe production of this plant from Cd-contaminated soils.

Feline calicivirus (FCV) causes upper respiratory tract diseases and even death in cats, thereby acting as a great threat to feline animals. Currently, FCV prevention is mainly achieved through vaccination, but the effectiveness of vaccination is limited. In this study, 105 FCV strain VP1 sequences with clear backgrounds were downloaded from the NCBI and subjected to a maximum likelihood method for systematic evolutionary analysis. Based on the genetic analysis results, FCV-positive sera were prepared using SPF mice and Chinese field cats as target animals, followed by a cross-neutralization assay conducted on the different genotype strains and in vivo challenge tests were carried out to further verify with the strain with best cross-protection effect. The results revealed that FCV was mainly divided into two genotypes: GI and GII. The GI genotype strains are prevalent worldwide, but all GII genotype strains were isolated from Asia, indicating a clear geographical feature. This may form resistance to FCV prevention in Asia. The in vitro neutralization assay conducted using murine serum demonstrated that the cross-protection effect varied among strains. A strain with broad-spectrum neutralization properties, DL39, was screened. This strain could produce neutralizing titers (10 × 2^3.08–10 × 2^0.25) against all strains used in this study. The antibody titers against the GI strains were 10 × 2^3.08–10 × 2^0.5 and those against the GII strains were 10 × 2^0.75–10 × 2^0.25. Preliminary evidence suggested that the antibody titer of the DL39 strain against GI was higher than that against GII. Subsequent cross-neutralization assays with cat serum prepared with the DL39 strain and each strain simultaneously yielded results similar to those described above. In vivo challenge tests revealed that the DL39 strain-immunized cats outperformed the positive controls in all measures. The results of several trials demonstrated that strain DL39 can potentially be used as a vaccine strain. The study attempted to combine the genetic diversity and phylogenetic analysis of FCV with the discovery of potential vaccines, which is crucial for developing highly effective FCV vaccines.

Feline panleucopenia virus (FPV) is a highly infectious pathogen that causes severe diseases in pets, economically important animals and wildlife in China. Although FPV was identified several years ago, little is known about how it overcomes the host innate immunity. In the present study, we demonstrated that infection with the FPV strain Philips-Roxane failed to activate the interferon β (IFN-β) pathway but could antagonize the induction of IFN stimulated by Sendai virus (SeV) in F81 cells. Subsequently, by screening FPV nonstructural and structural proteins, we found that only nonstructural protein 2 (NS2) significantly suppressed IFN expression. We demonstrated that the inhibition of SeV-induced IFN-β production by FPV NS2 depended on the obstruction of the IFN regulatory factor 3 (IRF3) signaling pathway. Further, we verified that NS2 was able to target the serine/threonine-protein kinase TBK1 and prevent it from being recruited by stimulator of interferon genes (STING) protein, which disrupted the phosphorylation of the downstream protein IRF3. Finally, we identified that the C-terminus plus the coiled coil domain are the key domains of NS2 that are required for inhibiting the IFN pathway. Our study has yielded strong evidence for the FPV mechanisms that counteract the host innate immunity.

Feline calicivirus (FCV) belongs to the family Caliciviridae, which includes important animal and human pathogens such as human norovirus and rabbit hemorrhagic disease virus. The fast evolution and great diversity of FCV make it highly difficult to develop vaccines that can induce sterilizing immunity. In this study, we evaluated the efficacy of a vaccine candidate generated via a replication-deficient vaccine strategy. Immunization with the vaccine generated a high level of neutralizing antibodies and highly reduced clinical outcomes against the challenge with a homologous virulent systemic feline calicivirus (VS-FCV) strain. Moreover, the VP1 gene of the vaccine was replaced with that derived from a heterologous virus strain. Vaccination with two combined virus constructs containing genetically distant VP1 genes led to the generation of broad neutralizing antibodies against FCV strains in cats. Notably, this replication-deficient FCV has the potential to serve as a viral vector vaccine, enabling the delivery of a foreign gene with stable genetics. In summary, this vaccine strategy holds great promise for developing safe, effective, and multivalent vaccines to prevent and control calicivirus infection. IMPORTANCE: FCV is one of the leading causes of respiratory diseases in cats. Over the last 20 years, certain strains evolved into VS-FCV, with severe symptoms and increased fatality. Updating and developing vaccines promptly are essential. Here, we employed reverse genetics to partially delete the VP2 gene of FCV, rescuing the replication-deficient vaccine candidate rHBDL2 FCV-△VP2. Immunization with this candidate generated high levels of neutralizing antibodies against FCV strains and significantly reduced clinical symptoms. Furthermore, the adaptability of this replication-defective FCV platform holds potential for the development of viral vector vaccines as well as multivalent vaccines, which are also crucial for the prevention and control of other calicivirus infections.

Background: Feline calicivirus (FCV), a pathogen that causes upper respiratory tract diseases in felids, primarily leads to oral ulcers and various respiratory symptoms, which can be fatal in severe cases. Currently, FCV prevention and control rely primarily on vaccination; however, the existing vaccine types in China are mainly inactivated vaccines, leading to a single prevention and control method with suboptimal outcomes. Methods and Results: This study commences with a genetic evolution analysis of Chinese FCV isolates, confirming the presence of two major genotypes, GI and GII with GI emerging as the dominant form. We subsequently selected the broadly neutralizing vaccine candidate strain DL39 as the template for the truncation and expression of multiple recombinant proteins. Through serological assays, we successfully confirmed the optimal protective antigen region, which is designated CE₃₉ (CDE). Further investigation revealed the location of the optimal protective antigen region within the CE region for both the GI and GII genotype strains. Capitalizing on this discovery, a bivalent recombinant protein, designated CE₃₉-CE_FB, was generated. Cat antisera generated against CE₃₉ and CE₃₉-CE_FB proteins were used in cross-neutralization against various strains of different genotypes, yielding high neutralization titers ranging from 1:45 to 1:15 and from 1:48 to 1:29, respectively, which surpassed those induced by antisera from cats vaccinated with Mi-aosanduo (commercial vaccine, strain 255). Ultimately, in vivo challenge experiments were per-formed after immunizing cats with the CE₃₉ and CE₃₉-CE_FB proteins, utilizing Miaosanduo as a control for comparison. The results demonstrated that immunization with both proteins effectively made cats less susceptible to FCV GI, GII, and VSD strains infection, resulting in superior immune efficacy compared with that in the Miaosanduo group. Conclusion: These results indicate that this study successfully identified the antigen CE₃₉, which has broad-spectrum antigenicity, through in vivo and in vitro experiments. These findings pre-liminarily demonstrate that the optimal protective antigen region of FCV strains is the CE region, laying a theoretical foundation for the development of novel broad-spectrum vaccines against FCV disease.